Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02346539 · ClinicalTrials.gov registry record · Phase 1
Effect of Nicotine on Brain Reward Pathways
A Phase 1 study of Depressive Disorder, sponsored by Mclean Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT02346539: Completed Phase 1 study of Depressive Disorder, sponsored by Mclean Hospital.
NCT02346539 is a Phase 1 study of Depressive Disorder that has completed, run by Mclean Hospital. The registered enrollment target is 46 participants, below the 331-participant average among 47 other Depressive Disorder trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02346539, a Phase 1 study of Depressive Disorder, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will determine whether an acute dose of nicotine, in the form of the nicotine lozenge, impacts brain and behavioral measures of mood and reward responsiveness in individuals with major depressive disorder.
Primary Outcome
Nicotine will enhance the fMRI BOLD response to monetary reinforcers relative to placebo administration
Conditions Studied
Interventions
- DRUG Nicotine polacrilex
Study Locations (1)
Massachusetts
- McLean Hospital - Belmont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2015-02 |
| Est. Completion | 2017-11 |
| Phase | Phase 1 |
What the finished NCT02346539 record still lists
NCT02346539 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 331-participant average among 47 other Depressive Disorder trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Nicotine polacrilex is the first listed.
NCT02346539 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02346539 about?
NCT02346539 is a clinical study titled "Effect of Nicotine on Brain Reward Pathways". The investigators will determine whether an acute dose of nicotine, in the form of the nicotine lozenge, impacts brain and behavioral measures of mood and reward responsiveness in individuals with major depressive disorder.
What is the current status of trial NCT02346539?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2015-02. Estimated completion is 2017-11.
What conditions does trial NCT02346539 study?
This clinical trial studies the following conditions: Depressive Disorder.
What interventions are being tested in trial NCT02346539?
The interventions under investigation include: Nicotine polacrilex (DRUG).
Who is sponsoring clinical trial NCT02346539?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02346539 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02346539's enrollment target sits among peer trials
46 36th of 47 higher than 12 of 47 other Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Therapist Behavior on the Treatment of Depressed Adolescents
COMPLETED · Phase 1
-
A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure
COMPLETED · Phase 1
-
A Mental Health Services Engagement Program for Racial and Ethnic Minority Young Adults
RECRUITING · NA
-
Development of a Transdiagnostic Intervention for Adolescents at Risk for Serious Mental Illness
RECRUITING · NA
-
Measurement-Based Care (MBC) Implementation, Effectiveness, and Mechanisms of Change
RECRUITING · NA
-
Research Evaluating Vagal Excitation AND Anatomical Links
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia